How Garvan Tall Poppy searches for prostate cancer gene
Dr Vanessa Hayes, head of the Cancer Genetics Group at the Garvan
Institute of Medical Research, today received a prestigious New South
Wales Young Tall Poppy Science Award in recognition of her research in
prostate cancer.
“I regard this area as very exciting because we know so little about
what predisposes men to prostate cancer,” she said. “We know the
disease runs in families. We also know it’s associated with certain
ethnic backgrounds. Both of these things tell us there has to be a
genetic element involved. While we have identified a region of a
chromosome that appears to be linked to prostate cancer, we have not
yet isolated a single prostate cancer gene. In that sense, we are
working in uncharted territory.”
Hayes and her team are starting to map out the territory, with the help
of very large samples of genetic and epidemiological data collected by
Professor Graham Giles, Melbourne-based epidemiologist. This
collaboration gives her access to collections of DNA from over 1,600
Australian men with prostate cancer, and 2,600 without.
In addition to taking a history of prostate cancer within the families
of these men, Giles and his team collect information about their
balding patterns, sexual habits, sexually transmitted diseases they
have had, presence of acne (or not) in their teenage years, when they
had their growth spurts and how many ejaculations they had in their
20s, 30s and 40s. Hayes and her team are able to correlate genetic
signatures to these traits, and ultimately to prostate cancer
predisposition.
Another project, even more ambitious in its scope, has had to be put on
hold while Hayes attempts to source funding from various government and
philanthropic agencies. She hopes to analyse DNA samples taken from a
large ‘admixed population’, a racially mixed group (in this case
African and European), where the ethnic populations have differences in
disease risk for prostate cancer. The plan is to use “admixture
mapping” to identify unusual patterns of inherited genetic variation
when compared with what is expected. This will help explain the
increased incidence of prostate cancer in this unique population
group.
Collaborating with a team at the Broad Institute in Boston, who have
developed very powerful software to analyse data such as this, Hayes is
optimistic that the value of the project will be recognised. “I have
access to some unique material,” she said. The African populations are
much older than the Caucasian populations – so they can teach us a lot
more genetically.”
Earlier this year, Vanessa Hayes was presented with The Premiers Award
for Outstanding Cancer Research 2007. This also recognised her
contributions towards furthering our understanding of prostate
cancer.
ABOUT GARVAN
The Garvan Institute of Medical Research was founded in 1963. Initially
a research department of St Vincent's Hospital in Sydney, it is now one
of Australia's largest medical research institutions with approximately
400 scientists, students and support staff. Garvan’s main research
programs are: Cancer, Diabetes & Obesity, Arthritis &
Immunology, Osteoporosis, and Neuroscience. The Garvan’s mission is to
make significant contributions to medical science that will change the
directions of science and medicine and have major impacts on human
health. The outcome of Garvan’s discoveries is the development of
better methods of diagnosis, treatment, and ultimately, prevention of
disease.
All media enquiries should be directed to:
Alison Heather 02 9295 8128 or Jackie Crossman 0402 218 662


